Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R; North American AA2500 T Gel Study Group.

J Clin Endocrinol Metab. 2003 Jun;88(6):2673-81.

PMID:
12788872
2.
3.

Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.

Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N; Testosterone Gel Study Group.

J Clin Endocrinol Metab. 2000 Aug;85(8):2839-53.

PMID:
10946892
4.

AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

Seidman SN, Klein DF.

J Clin Endocrinol Metab. 2004 Dec;89(12):6358-9. No abstract available.

PMID:
15579803
5.
6.

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS.

J Clin Endocrinol Metab. 2004 May;89(5):2085-98.

PMID:
15126525
7.

Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.

Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S.

J Clin Endocrinol Metab. 2005 Sep;90(9):5226-33. Epub 2005 Jul 12.

PMID:
16014407
8.

Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study.

Miller KK, Biller BM, Beauregard C, Lipman JG, Jones J, Schoenfeld D, Sherman JC, Swearingen B, Loeffler J, Klibanski A.

J Clin Endocrinol Metab. 2006 May;91(5):1683-90. Epub 2006 Feb 14.

PMID:
16478814
9.

Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.

Rogol AD, Tkachenko N, Bryson N.

Andrology. 2016 Jan;4(1):46-54. doi: 10.1111/andr.12137. Epub 2015 Dec 22. Erratum in: Andrology. 2017 Jul;5(4):844.

10.

Review of Testim gel.

McNicholas T, Ong T.

Expert Opin Pharmacother. 2006 Mar;7(4):477-84. Review.

PMID:
16503819
11.

Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.

Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N.

J Clin Endocrinol Metab. 2000 Dec;85(12):4500-10.

PMID:
11134099
12.

Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.

Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA.

Clin Endocrinol (Oxf). 1997 Dec;47(6):727-37.

PMID:
9497881
13.
14.
15.

Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.

Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB.

Arch Intern Med. 2005 Jul 25;165(14):1582-9.

PMID:
16043675
16.

Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.

Behre HM, Heinemann L, Morales A, Pexman-Fieth C.

Aging Male. 2008 Jun;11(2):101-6. doi: 10.1080/13685530802169723.

PMID:
18570063
17.

Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study.

Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R.

Menopause. 2006 Sep-Oct;13(5):770-9. Erratum in: Menopause. 2007 Jan-Feb;14(1):157.

PMID:
16932240
18.

Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels.

Bhasin S, Storer TW, Asbel-Sethi N, Kilbourne A, Hays R, Sinha-Hikim I, Shen R, Arver S, Beall G.

J Clin Endocrinol Metab. 1998 Sep;83(9):3155-62.

PMID:
9745419
19.

Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.

Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL.

J Clin Endocrinol Metab. 2005 Mar;90(3):1502-10. Epub 2004 Nov 30.

PMID:
15572415
20.

A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up.

Behre HM, Tammela TL, Arver S, Tolrá JR, Bonifacio V, Lamche M, Kelly J, Hiemeyer F; European Testogel® Study Team, Giltay EJ, Gooren LJ.

Aging Male. 2012 Dec;15(4):198-207. doi: 10.3109/13685538.2012.699562. Epub 2012 Jul 26.

PMID:
22834649

Supplemental Content

Support Center